Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aura Biosciences (AURA) EPS (Basic) (2020 - 2026)

Aura Biosciences filings provide 7 years of EPS (Basic) readings, the most recent being -$0.5 for Q1 2026.

  • Quarterly EPS (Basic) rose 9.09% to -$0.5 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.74 through Mar 2026, up 8.42% year-over-year, with the annual reading at -$1.76 for FY2025, 0.57% down from the prior year.
  • EPS (Basic) hit -$0.5 in Q1 2026 for Aura Biosciences, down from -$0.37 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.37 in Q4 2025 and bottomed at -$0.55 in Q1 2025.
  • Average EPS (Basic) over 5 years is -$0.47, with a median of -$0.47 recorded in 2025.
  • Peak annual rise in EPS (Basic) hit 98.39% in 2022, while the deepest fall reached 100.75% in 2022.
  • Aura Biosciences' EPS (Basic) stood at -$0.52 in 2022, then increased by 3.85% to -$0.5 in 2023, then dropped by 4.0% to -$0.52 in 2024, then increased by 28.85% to -$0.37 in 2025, then plummeted by 35.14% to -$0.5 in 2026.
  • Per Business Quant, the three most recent readings for AURA's EPS (Basic) are -$0.5 (Q1 2026), -$0.37 (Q4 2025), and -$0.4 (Q3 2025).